Navigation Links
Metformin does not improve heart function in patients without diabetes
Date:3/31/2014

Although some research has suggested that metformin, a medication often used in the treatment of diabetes, may have favorable effects on ventricular (heart) function, among patients without diabetes who underwent percutaneous coronary intervention (PCI; a procedure such as stent placement used to open narrowed coronary arteries) for ST-segment elevation myocardial infarction (STEMI; a certain pattern on an electrocardiogram following a heart attack), treatment with metformin did not result in improved ventricular function, according to a JAMA study released online to coincide with its presentation at the 2014 American College of Cardiology Scientific Sessions.

Treatment for STEMI includes immediate treatment with anticlotting medications and PCI to restore coronary blood flow. STEMI results in left ventricular dysfunction (decreased pump function) in up to 50 percent of patients, and approximately 20 percent to 40 percent of patients develop heart failure sometime after STEMI; heart failure after STEMI is associated with a 3 to 4 times higher risk of death. Left ventricular dysfunction is regarded as the strongest predictor for adverse outcome after STEMI, according to background information in the article.

Chris P. H. Lexis, M.D., of the University of Groningen, Groningen, the Netherlands, and colleagues randomly assigned 380 patients who underwent PCI for STEMI to receive metformin hydrochloride or placebo twice daily for 4 months to determine whether metformin helps preserve left ventricular function after STEMI in patients without diabetes. Left ventricular ejection fraction (a measure of how well the left ventricle of the heart pumps blood with each contraction) was assessed by magnetic resonance imaging.

Left ventricular ejection fraction 4 months after beginning the study did not differ between the metformin group (53.1 percent) and the placebo group (54.8 percent). In addition, N-terminal pro-brain natriuretic peptide level (a cardiac biomarker) was not different between the 2 groups.

Major adverse cardiac events were observed in 6 patients (3.1 percent) in the metformin group and in 2 patients (1.1 percent) in the placebo group.

"Because left ventricular function is currently regarded as the most important predictor of morbidity and mortality after STEMI, it is unlikely that metformin will have a significant effect on long-term outcome after STEMI in patients without diabetes," the authors write.

"The present findings do not support the use of metformin in this setting."


'/>"/>

Contact: Iwan C.C. van der Horst, M.D., Ph.D.
i.c.c.van.der.horst@umcg.nl
The JAMA Network Journals
Source:Eurekalert

Related medicine news :

1. Diabetes drug metformin with chemo and radiation may improve outcomes in lung cancer patients
2. Metformin's Anti-Cancer Properties Clarified in an Obesity Cell Model of Pancreatic Cancer
3. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin), KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone) Now Available in Pharmacies in the United States
4. Metformin Wont Aid Breast Cancer Survival in Diabetics
5. Added benefit of saxagliptin/metformin combination is not proven
6. Metformin improves blood glucose levels and BMI in very obese children
7. Study: Metformin offers cardio benefits over sulfonylureas in diabetes
8. Metformin may lower cancer risk in people with Type 2 diabetes
9. Metformin Outperforms Common Class of Diabetes Drugs in Study
10. Value of Metformin, Insulin Combo for Type 2 Diabetes Questioned
11. Repeated hUCB injections may improve prognosis of children with deadly inherited disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... ... be speaking on how healthcare companies can use newly released government data on ... of a population and intervene and capture the value they create to succeed ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... only four states in the U.S. require dental technicians to be certified or ... the dental industry, NADL created the “What’s In Your Mouth?” campaign to inform ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart ... employers and organizations with the tools and information to lower the costs, and ... cut the cost of providing employee healthcare benefits by as much as 22%:, ...
(Date:2/6/2016)... ... , ... US Sports Camps is proud to sponsor the Bay Area Disc ... non-profit leaders, ultimate organizations, and coaches from around the US. The theme for this ... Director of Youth and Education, describes this year YUCC as “an important conversation we ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research ... treatment helps to reduce the frequency and level of relapse. , ... Healthy Identity and Purpose,” will explore the critical tasks of the recovery phase ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , February 8, 2016 ... new report published by Allied Market Research titled, ... Opportunities and Forecasts, 2014-2020", estimates the world synthetic ... Nucleotide synthesis and sequencing technology segment would continue ... and software tools segment, collectively, held around half ...
(Date:2/5/2016)... HILL, N.C. , Feb. 5, 2016  Despite ... has been slower than other industries to embrace Big ... come with utilization. On the medical side, organizations have ... improve everything from clinical trials to adherence. ... research from benchmarking firm Best Practices, LLC, Big Data ...
(Date:2/5/2016)... , Feb. 5, 2016  Syneron Medical ... aesthetic device company, announced today that William ... North America, is scheduled to participate in the ... Conference on February 11, 2016 in ... allow institutional investors to meet with the Mr. ...
Breaking Medicine Technology: